

We Claim:

1. A stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody in a concentration of 20 mg/ml to 125 mg/ml, a buffer, polysorbate in a concentration of 0.005% (w/v) to 0,06% (w/v), and pH of 6.0, wherein the formulation further comprises

a) trehalose in a concentration of 180 mM to 240 mM or

b) Mannitol in a concentration of 180 mM to 240 mM and Sucrose in a concentration of 10 mM to 50mM,

and wherein said anti-CD19 antibody comprises a heavy chain constant domain of the sequence
 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
 SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGDPVFLFPPKPK
 DTLNISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD
 WLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
 VEWESNGQPENNYKTTTPMLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSL
 SLSPGK (SEQ ID NO: 8) and a light chain constant domain of the sequence
 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
 STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 9).

2. The formulation of claim 1, wherein said anti-CD19 antibody in the formulation is 40 mg/ml.

3. The formulation of any one of claims 1 or 2, wherein said buffer is citrate buffer or phosphate buffer.

4. The formulation of claim 3, wherein said citrate buffer or phosphate buffer are in a concentration of between 20 and 50mM.

5. The formulation of claim 4, wherein said citrate buffer or phosphate buffer are in a concentration of 25mM.

6. The formulation of any one of claims 1-5, wherein said trehalose in the formulation is 200 mM.

7. The formulation of any one of claims 1-5, wherein said Mannitol in the formulation is 219 mM and said Sucrose in the formulation is 29 mM.

8. The formulation of any one of claims 1-7 wherein said polysorbate in the formulation is polysorbate 20.
9. The formulation of any one of claims 1-8, wherein said polysorbate in the formulation is 0.02%.
10. The formulation of any one of claims 1-9, wherein said anti-CD19 antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
11. The formulation of any one of claims 1-10, wherein the formulation is stable at 2-8°C for at least 6 months, at least 12 months, at least 18 months, at least 24 months or at least 36 months.
12. The formulation of any one of claims 1-5, wherein said anti-CD19 antibody is in an amount of 40 mg/mL, said citrate buffer in a concentration of 25 mM, said trehalose in a concentration of 200 mM, polysorbate in a concentration of 0.02% (w/v) and said formulation has a pH of 6.0.
13. The formulation of any one of claims 1-5, wherein said anti-CD19 antibody is in an amount of 40 mg/mL, said citrate buffer in a concentration of 25 mM, said mannitol in a concentration of 219 mM and said sucrose in a concentration of 29mM, polysorbate in a concentration of 0.02% (w/v) and said formulation has a pH of 6.0.
14. An article of manufacture comprising a container holding the stable lyophilized pharmaceutical formulation of any one of claims 1-13.
15. A method of treating a disease or disorder in a subject comprising administering an effective amount of the formulation of any one of claims 1-13 to the subject, wherein the disease or disorder is cancer.